<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9084">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988674</url>
  </required_header>
  <id_info>
    <org_study_id>P15-672</org_study_id>
    <nct_id>NCT02988674</nct_id>
  </id_info>
  <brief_title>A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation</brief_title>
  <official_title>Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to access retention rate, persistence and adherence in
      population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis
      (PsA)) participants treated with adalimumab in routine clinical settings in the Russian
      Federation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants on adalimumab therapy</measure>
    <time_frame>Up to 30 days after administering last dose in the study (52 weeks)</time_frame>
    <description>This is used to assess retention rate. Persistence/Adherence of SpA patient to treatment, as well as retention rate, is an important factor of achieving of treatment goals. Medical non-adherence poses a significant limitation to treating to target in rheumatoid arthritis (RA) and SpA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants on adalimumab therapy</measure>
    <time_frame>Up to 30 days after administering last dose in the study (52 weeks)</time_frame>
    <description>This is used to assess retention rate. Persistence/Adherence of SpA patient to treatment, as well as retention rate, is an important factor of achieving of treatment goals. Medical non-adherence poses a significant limitation to treating to target in RA and SpA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing medication adherence</measure>
    <time_frame>Up to 48 weeks of treatment period</time_frame>
    <description>Medication adherence is defined as the extent to which a participant acts in accordance with the prescribed interval and dose of a dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing medication persistence</measure>
    <time_frame>Up to 48 weeks of treatment period</time_frame>
    <description>Medication persistence is defined as the duration of time from initiation to discontinuation of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of disease activity in participants with AS</measure>
    <time_frame>Up to 48 weeks of treatment period</time_frame>
    <description>This is assessed using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in participants with AS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of disease activity in participants with PsA</measure>
    <time_frame>Up to 48 weeks of treatment period</time_frame>
    <description>This is assessed using Disease activity score 28 joints count (DAS28) in participants with PsA.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">139</enrollment>
  <condition>Spondylarthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Participants with Spondylarthritis</arm_group_label>
    <description>Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) participants treated
        with adalimumab in routine clinical settings in the Russian Federation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of AS or PsA.

          -  Planned prescription or prescribed no more than 1 month before to enrolment therapy
             with adalimumab. Treatment has to be prescribed according to the local product label
             and prescription guidelines.

          -  At the moment of start of treatment with adalimumab moderate/severe AS or PsA (BASDAI
             &gt; 4 for AS; DAS28 &gt;3,2 for PsA).

          -  Negative result of tuberculosis (TB) screening test and TB specialist permission to
             start biologic therapy.

          -  Authorization (Consent) for Use/Disclosure of Data signed by the participant.

        Exclusion Criteria:

          -  Has contraindications for the treatment with adalimumab (please see the latest
             version of the locally approved label).

          -  Participants who are unable to walk and perform basic self-care activities either due
             to SpA or a comorbid condition.

          -  Any biologic drugs taken over before 3 months of enrolment to the study.

          -  Previous participation in this program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrey Strugovschikov, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Anikin, MD</last_name>
    <phone>+7 (495) 258 42 77 ext. 56225</phone>
    <email>alexander.anikin@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrey Potapov, MD</last_name>
    <email>andrey.potapov@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154381</name>
      <address>
        <city>Khanty-Mansiysk</city>
        <zip>628011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154381, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141822</name>
      <address>
        <city>Khimki</city>
        <zip>141400</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154374</name>
      <address>
        <city>Moscow</city>
        <zip>107023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154374, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154375</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154375, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154378</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154378, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154382</name>
      <address>
        <city>Moscow</city>
        <zip>117041</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154382, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154373</name>
      <address>
        <city>Moscow</city>
        <zip>117546</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154373, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154379</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154379, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154377</name>
      <address>
        <city>Moscow</city>
        <zip>127572</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154377, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154376</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154376, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154380</name>
      <address>
        <city>Tula</city>
        <zip>300031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155539</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155539, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154383</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154383, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 11, 2017</lastchanged_date>
  <firstreceived_date>November 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>Humira®</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Spondylarthritis</keyword>
  <keyword>Psoriatic arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
